Oncolines unveils new State-of-the-Art Laboratories
In a significant stride towards advancing cancer research and drug development, Oncolines, has officially received the keys to its new laboratories and offices situated within the prestigious Curie Building on the Pivot Park in Oss, the Netherlands.
Our Article Published in the Journal of Medicinal Chemistry
Symeres is thrilled to announce the publication of a scientific article in the prestigious Journal of Medicinal Chemistry with our colleague Koen Hekking as the main author and many more Symerians involved! We are incredibly proud of our colleagues who were instrumental in the research and development of this innovative project.
Peter Molenveld Assumes Role as Secretary of KNCV (Royal Netherlands Chemical Society)
Symeres is proud to announce that our colleague Dr. Peter Molenveld has been appointed as a board member of the Royal Netherlands Chemical Society (KNCV). His appointment as Secretary marks a crucial milestone in Molenveld’s career and signifies his commitment to advancing the interests of the chemical community in the Netherlands.
Luc van Hijfte Assumes Presidency of EFMC, Spearheading Advances in Medicinal Chemistry and Chemical Biology
Symeres is thrilled to announce that as of January 1, 2024, our sr. Vice President Dr. Luc van Hijfte has taken the helm as the President of the European Federation of Medicinal Chemistry and Chemical Biology (EFMC).
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same (Organix)
Number: US 2023/0056273 A1
Triazole derivatives and their use as tankyrase inhibitors
Number: WO 2022/008896 A1
Conjugate of saponin, oligonucleotide and galnac
Number: WO 2022/055351 A1
Specific N-terminal attachment of TMTHSI linkers to native peptides and proteins for strain-promoted azide alkyne cycloaddition
Article: Chem. Commun., 2023, Advance Article
Contemporary Chiral Resolutions
Article: Chim. Oggi., 2023, 41 (2)
Comparative biochemical kinase activity analysis identifies rivoceranibas a highly selective VEGFR2 inhibitor (Oncolines)
Article: Cancer Chemother Pharmacol., 2023 (6), 491-499
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.